Crossject Total Liabilities
Crossject total liabilities. Based on the latest financial reports, Crossject (ALCJ) has total liabilities worth €35.30 Million EUR (≈ $41.27 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check Crossject liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Total Liabilities of Crossject (2010–2025)
Total liabilities of Crossject from 2010 to 2025. This chart illustrates how Crossject's total liabilities have evolved over time, based on quarterly financial data. Explore ALCJ long-term investment intensity to see how much of total assets are deployed in long-term investments.
Crossject Competitors by Total Liabilities
The table below lists competitors of Crossject ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Manba Finance Ltd
NSE:MANBA
|
India | Rs14.99 Billion |
|
Moda-InnoChips Co. Ltd
KQ:080420
|
Korea | ₩665.34 Billion |
|
Inoue Rubber (Thailand) Public Company Limited
BK:IRC
|
Thailand | ฿1.12 Billion |
|
MAISON POMMERY & ASSOCIES
PA:POMRY
|
France | €903.27 Million |
|
Erbud SA
WAR:ERB
|
Poland | zł1.37 Billion |
|
Kilitch Drugs (India) Limited
NSE:KILITCH
|
India | Rs1.34 Billion |
|
POLARIS WORKS Inc
KQ:123010
|
Korea | ₩21.88 Billion |
|
PolyPid
NASDAQ:PYPD
|
USA | $11.33 Million |
Liability Composition Analysis (2010–2025)
This chart breaks down Crossject's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see ALCJ total assets.
Liquidity & Leverage Metrics
Crossject Total Liabilities Ratios Explained
Crossject total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 2.35 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -7.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.16 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Crossject's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Crossject (2010–2025)
The table below shows the annual total liabilities of Crossject from 2010 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | €35.30 Million ≈ $41.27 Million |
+3.10% |
| 2024-12-31 | €34.24 Million ≈ $40.03 Million |
+0.97% |
| 2023-12-31 | €33.91 Million ≈ $39.64 Million |
+12.38% |
| 2022-12-31 | €30.17 Million ≈ $35.28 Million |
-18.46% |
| 2021-12-31 | €37.01 Million ≈ $43.26 Million |
+6.58% |
| 2020-12-31 | €34.72 Million ≈ $40.59 Million |
+61.63% |
| 2019-12-31 | €21.48 Million ≈ $25.11 Million |
+16.08% |
| 2018-12-31 | €18.50 Million ≈ $21.63 Million |
+59.11% |
| 2017-12-31 | €11.63 Million ≈ $13.60 Million |
+46.01% |
| 2016-12-31 | €7.97 Million ≈ $9.31 Million |
+56.75% |
| 2015-12-31 | €5.08 Million ≈ $5.94 Million |
+30.64% |
| 2014-12-31 | €3.89 Million ≈ $4.55 Million |
-17.28% |
| 2013-12-31 | €4.70 Million ≈ $5.50 Million |
+4.54% |
| 2012-12-31 | €4.50 Million ≈ $5.26 Million |
-10.71% |
| 2011-12-31 | €5.04 Million ≈ $5.89 Million |
-54.46% |
| 2010-12-31 | €11.06 Million ≈ $12.93 Million |
-- |
About Crossject
Crossject Société Anonyme develops needle-free injection systems in France. The company develops ZENEO, needle-free, pre-filled, single-use auto-injector. Its product pipeline includes Midazolam for epileptic seizure; Naloxone for opioid overdose; Terbutaline for the treatment of severe asthma crisis; Epinephrine for anaphylactic shock; and Sumatriptan for the treatment of migraine and cluster he… Read more